SCHEMBL769677

SCHEMBL769677

CCCc1ccc(-n2cnc3cc(NCc4ccc(C(C)C)cc4)ccc32)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 15/20 0.65
NPC1 O15118 14/20 0.65
POLB P06746 1/20 0.65
KDM4E B2RXH2 8/20 0.55
SMN1; SMN2 Q16637 6/20 0.55
MAPT P10636 6/20 0.55
ALDH1A1 P00352 6/20 0.55
HPGD P15428 5/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
HTT P42858 3/20 0.55
TDP1 Q9NUW8 2/20 0.55
MAPK1 P28482 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
KIT P10721 2/20 0.53
FLT3 P36888 2/20 0.53
GAA P10253 4/20 0.51
HSD17B10 Q99714 3/20 0.51
LMNA P02545 2/20 0.51
ALOX15 P16050 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL769336 0.94 RAB9A (0.63) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL769480 0.92 RAB9A (0.61) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL769029 0.91 RAB9A (0.68) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL770705 0.91 RAB9A (0.64) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL769840 0.88 RAB9A (0.61) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL769960 0.88 RAB9A (0.61) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL770450 0.88 MAPT (0.65) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL769479 0.86 RAB9A (0.64) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL770154 0.86 RAB9A (0.64) RAB9ANPC1POLBKDM4ESMN1; SMN2
SCHEMBL769843 0.86 RAB9A (0.64) RAB9ANPC1POLBKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US claimed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US claimed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-8871746-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2014-10-28 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection SIGA TECHNOLOGIES INC. (US) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071447-A1 Antiviral Drugs for Treatment of Arenavirus Infection ZC3HAV1, GZMB, GTF3C3 RAB9A 3973/4885NPC1 337/4885POLB 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.